- Home
- ICCC vs PLUR Comparison
ICCC vs PLUR Comparison
Compare ICCC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- PLUR
- Stock Information
- Founded
- ICCC 1982
- PLUR 2001
- Country
- ICCC United States
- PLUR Israel
- Employees
- ICCC N/A
- PLUR N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCC Health Care
- PLUR Health Care
- Exchange
- ICCC Nasdaq
- PLUR Nasdaq
- Market Cap
- ICCC 28.7M
- PLUR 30.2M
- IPO Year
- ICCC 1987
- PLUR N/A
- Fundamental
- Price
- ICCC $3.55
- PLUR $4.75
- Analyst Decision
- ICCC
- PLUR
- Analyst Count
- ICCC 0
- PLUR 0
- Target Price
- ICCC N/A
- PLUR N/A
- AVG Volume (30 Days)
- ICCC 20.8K
- PLUR 16.3K
- Earning Date
- ICCC 11-13-2024
- PLUR 11-11-2024
- Dividend Yield
- ICCC N/A
- PLUR N/A
- EPS Growth
- ICCC N/A
- PLUR N/A
- EPS
- ICCC N/A
- PLUR N/A
- Revenue
- ICCC $23,222,929.00
- PLUR $326,000.00
- Revenue This Year
- ICCC N/A
- PLUR N/A
- Revenue Next Year
- ICCC N/A
- PLUR N/A
- P/E Ratio
- ICCC N/A
- PLUR N/A
- Revenue Growth
- ICCC 48.05
- PLUR 13.59
- 52 Week Low
- ICCC $3.34
- PLUR $3.44
- 52 Week High
- ICCC $5.59
- PLUR $8.48
- Technical
- Relative Strength Index (RSI)
- ICCC 43.90
- PLUR 41.21
- Support Level
- ICCC $3.51
- PLUR $4.54
- Resistance Level
- ICCC $3.74
- PLUR $5.34
- Average True Range (ATR)
- ICCC 0.17
- PLUR 0.36
- MACD
- ICCC 0.00
- PLUR -0.05
- Stochastic Oscillator
- ICCC 18.60
- PLUR 25.56
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.